Canada · Delayed Price · Currency is CAD Microbix Biosystems Earnings Call Transcripts
Fiscal Year 2026
-
Q3 saw 17% year-over-year revenue growth, improved gross margins, and strong cash reserves. Operational efficiencies, B2C sales growth, and progress on major projects like Kinlytic and QAPs commercialization support a positive outlook for Q4.
-
Q2 saw revenues fall below breakeven due to a sharp drop in Chinese sales and delayed antigen orders, but non-China business grew and cost controls remain strong. QAPs revenues are expected to rebound, and Kinlytic's launch is on track for 2028, with a solid cash position supporting ongoing investments.
-
Q1 2026 revenue rebounded 13% sequentially to CAD 4.2 million, with net loss managed by cash reserves. Growth in QAPs and new client wins offset ongoing weakness in China, while annual revenue is targeted at CAD 18.5–19 million. NCIB share buybacks continue at 15,000 shares per day.
Fiscal Year 2025
-
Revenue declined 27% year-over-year due to major client losses and a milder respiratory season, but underlying product sales and royalties grew in most categories. Operational improvements, strong cash reserves, and new product launches position the company for recovery and growth in fiscal 2026.
-
Q3 fiscal 2025 saw a sharp revenue decline and net loss due to setbacks with two major clients, but recurring sales and key business lines excluding those clients showed double-digit growth. Management is focused on rebuilding sales, launching new products, and leveraging strong liquidity to support recovery.
-
Q2 saw strong antigen sales and margin gains, offset by temporary QAPs softness and anticipated second-half revenue headwinds from China. Strategic progress continues with new capabilities, customer onboarding, and robust financial health.
-
Recurring product sales grew 40% year-over-year, with gross margins expanding to 62% and net earnings of CAD 856,000. Strategic moves into recombinant antigens and new QAPs markets support a 20%-40% revenue growth target, while strong cash reserves and share buybacks enhance shareholder value.
Fiscal Year 2024
-
Record revenue and margin growth in both antigens and QAPs segments drove a strong fiscal year, with continued investment in capacity, innovation, and share buybacks. Outlook remains robust, targeting 20%-40% annual revenue growth and further margin expansion.
-
Q3 saw 20% year-over-year recurring sales growth and a 54% gross margin, with strong performance in antigens and QAPs. The outlook remains robust, targeting 20%-40% sales growth in 2025, supported by a strong order book, capacity expansion, and disciplined cost control.